Compare SFBC & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFBC | ANIX |
|---|---|---|
| Founded | 1953 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.7M | 103.9M |
| IPO Year | 2012 | 2013 |
| Metric | SFBC | ANIX |
|---|---|---|
| Price | $46.60 | $2.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | 2.0K | ★ 215.6K |
| Earning Date | 11-06-2026 | 09-09-2026 |
| Dividend Yield | ★ 1.88% | N/A |
| EPS Growth | ★ 53.89 | 12.82 |
| EPS | ★ 1.59 | N/A |
| Revenue | N/A | ★ $210,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $28.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.68 | $2.32 |
| 52 Week High | $49.21 | $5.46 |
| Indicator | SFBC | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 53.51 | 54.87 |
| Support Level | $45.18 | $2.82 |
| Resistance Level | $46.77 | $3.09 |
| Average True Range (ATR) | 0.86 | 0.14 |
| MACD | 0.34 | 0.03 |
| Stochastic Oscillator | 63.54 | 63.98 |
Sound Financial Bancorp Inc operates as the holding company for Sound Community Bank that provides traditional banking and other financial services for individuals and businesses. It attracts retail and commercial deposits from the public and invests those funds, along with borrowed funds, in loans secured by first and second mortgages on one-to-four-family residences including home equity loans and lines of credit, commercial and multifamily real estate, construction and land, consumer and commercial business loans. The bank also offers secured and unsecured consumer loan products, including manufactured home loans, floating home loans, automobile loans, boat loans, and recreational vehicle loans.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.